 Carcinoma, Hepatocellular
"Carcinoma, Hepatocellular" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Descriptor ID |
D006528
|
| MeSH Number(s) |
C04.557.470.200.025.255 C04.588.274.623.160 C06.301.623.160 C06.552.697.160
|
| Concept/Terms |
Carcinoma, Hepatocellular- Carcinoma, Hepatocellular
- Carcinomas, Hepatocellular
- Hepatocellular Carcinomas
- Liver Cell Carcinoma, Adult
- Liver Cancer, Adult
- Adult Liver Cancer
- Adult Liver Cancers
- Cancer, Adult Liver
- Cancers, Adult Liver
- Liver Cancers, Adult
- Liver Cell Carcinoma
- Carcinoma, Liver Cell
- Carcinomas, Liver Cell
- Cell Carcinoma, Liver
- Cell Carcinomas, Liver
- Liver Cell Carcinomas
- Hepatocellular Carcinoma
- Hepatoma
- Hepatomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Hepatocellular".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Hepatocellular".
This graph shows the total number of publications written about "Carcinoma, Hepatocellular" by people in this website by year, and whether "Carcinoma, Hepatocellular" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 4 | 1 | 5 | | 2002 | 1 | 1 | 2 | | 2003 | 2 | 1 | 3 | | 2004 | 5 | 1 | 6 | | 2005 | 4 | 2 | 6 | | 2006 | 3 | 2 | 5 | | 2007 | 11 | 1 | 12 | | 2008 | 10 | 1 | 11 | | 2009 | 12 | 1 | 13 | | 2010 | 14 | 1 | 15 | | 2011 | 14 | 2 | 16 | | 2012 | 9 | 1 | 10 | | 2013 | 16 | 3 | 19 | | 2014 | 12 | 2 | 14 | | 2015 | 11 | 1 | 12 | | 2016 | 14 | 2 | 16 | | 2017 | 9 | 0 | 9 | | 2018 | 14 | 0 | 14 | | 2019 | 9 | 2 | 11 | | 2020 | 13 | 0 | 13 | | 2021 | 9 | 0 | 9 | | 2022 | 15 | 1 | 16 | | 2023 | 19 | 0 | 19 | | 2024 | 20 | 2 | 22 | | 2025 | 26 | 1 | 27 | | 2026 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Hepatocellular" by people in Profiles.
-
Endo Y, Kawashima J, Chatzipanagiotou O, Woldesenbet S, Aucejo F, Marques HP, Lam V, Lesurtel M, Popescu I, Weiss M, Martel G, Poultsides GA, Ruzzenente A, Endo I, Gleisner A, Shen F, Pawlik TM. Machine learning-based clustering differentiates bilateral hepatocellular carcinoma characteristics and prognosis. Surgery. 2026 Jun; 194:110186.
-
Gu W, Ren Z, Gao J, Shen Z, Wang Y, Xu L, Qian R, Miao Q, Wu Y, Hu X, Wu Y, Liu W, Wan CC, Sun L, Cai Y, Sang M, Zheng C, Yan T. Inhibiting NAT10 suppresses hepatocellular carcinoma progression by reducing Nrf2 mRNA stability and increasing oxidative stress. Chem Biol Interact. 2026 Apr 25; 429:111972.
-
Malavia M, Eliason G, Eggers LA, Arne A, Marchak K, Hart J, Lindquist J, Trivedi P, Casadaban L. Yttrium-90 radioembolization for primary and metastatic liver tumors exhibiting arterial-phase hypovascularity. Sci Rep. 2026 Jan 15; 16(1):4588.
-
Afyouni S, Zandieh G, Pawlik TM, Kamel IR. Functional imaging: a game changer for biomarker discovery and treatment response among patients with hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2026 Jan; 20(1):29-38.
-
Prawira A, Xu H, Mei Y, Leow WQ, Nasir NJM, Reolo MJ, Otsuka M, Rahbari M, Chen Z, Weerasooriya M, Abdullah LB, Wu J, Hazirah SN, Wasser M, Chung A, Goh BK, Chow PK, Albani S, Lee J, Lim TKH, Zhai W, Dan YY, Goh GB, Heikenwälder MF, Zhang Y, Dasgupta R, Tai WMD, Liu H, Chen J, Chew V. Targeting Treg-fibroblast interaction to enhance immunotherapy in steatotic liver disease-related hepatocellular carcinoma. Gut. 2025 Dec 05; 75(1):105-118.
-
Chatzipanagiotou OP, Catalano G, Mujtaba K, Kawashima J, Altaf A, Cauchy F, Aucejo F, Marques HP, Lam V, Hugh T, Popescu I, Kitago M, Weiss M, Martel G, Ratti F, Poultsides GA, Ruzzenente A, Endo I, Gleisner A, Pawlik TM. Perioperative changes in ALBI and platelets (CAP): association with postoperative complications among patients undergoing surgery for hepatocellular carcinoma. HPB (Oxford). 2026 Mar; 28(3):389-398.
-
Akabane M, Baldo A, Kawashima J, Woldesenbet S, Lesurty M, Aucejo F, Popescu I, Kitago M, Martel G, Ratti F, Aldrighetti L, Poultsides GA, Imaoka Y, Ruzzenente A, Endo I, Gleisner A, Marques HP, Lam V, Hugh T, Bhimani N, Shen F, Pawlik TM. Beyond the composite: Differential impact of albumin and bilirubin relative to tumor burden in HCC. Eur J Surg Oncol. 2026 Feb; 52(2):111309.
-
Schwenk S, Kaplan DE. Chemoprevention of hepatocellular carcinoma. Hepatol Commun. 2025 Nov 01; 9(11).
-
Akabane M, Kawashima J, Altaf A, Woldesenbet S, Cauchy F, Aucejo F, Popescu I, Kitago M, Martel G, Ratti F, Aldrighetti L, Poultsides GA, Imaoka Y, Ruzzenente A, Endo I, Gleisner A, Marques HP, Lam V, Hugh T, Bhimani N, Shen F, Pawlik TM. Minimally invasive surgery for hepatocellular carcinoma: evolving trade-offs of patient selection and recurrence risk. J Gastrointest Surg. 2026 01; 30(1):102272.
-
Akabane M, Kawashima J, Woldesenbet S, Thammachack R, Cauchy F, Aucejo F, Popescu I, Kitago M, Martel G, Ratti F, Aldrighetti L, Poultsides GA, Imaoka Y, Ruzzenente A, Endo I, Gleisner A, Marques HP, Lam V, Hugh T, Bhimani N, Shen F, Pawlik TM. The surgical burden score: a novel continuous metric to predict postoperative complications after hepatectomy for hepatocellular carcinoma. HPB (Oxford). 2025 Nov; 27(11):1445-1454.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|